Skip to main content

Publications

featured publications

  • Safety and Survival Outcomes of Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior Ra treatment: The RALU Study.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    Authors: Kambiz Rahbar, Markus Essler, Kim M Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A Bundschuh, Wolfgang P Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor

  • Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.

    Frontiers in oncology

    Authors: Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C Kalff, Christian P Strassburg, Maria A Gonzalez-Carmona

  • Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.

    The Prostate

    Authors: Philipp E Hartrampf, Franz-Xaver Weinzierl, Anna Katharina Seitz, Hubert Kübler, Markus Essler, Andreas K Buck, Rudolf A Werner, Ralph A Bundschuh

  • mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.

    European journal of nuclear medicine and molecular imaging

    Authors: Philipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, Sebastian E Serfling, Aleksander Kosmala, Anna Katharina Seitz, Hubert Kübler, Andreas K Buck, Markus Essler, Rudolf A Werner

  • A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.

    Frontiers in oncology

    Authors: Yutao Li, Amit Sharma, Xiaolong Wu, Hans Weiher, Dirk Skowasch, Markus Essler, Ingo G H Schmidt-Wolf

  • Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy.

    Clinical nuclear medicine

    Authors: Sebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, Takahiro Higuchi, Steven P Rowe, Lena Bundschuh, Markus Essler, Andreas K Buck, Ralph Alexander Bundschuh, Rudolf A Werner

  • Matched-pair analysis of [Lu]Lu-PSMA I&T and [Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

    European journal of nuclear medicine and molecular imaging

    Authors: Philipp E Hartrampf, Franz-Xaver Weinzierl, Andreas K Buck, Steven P Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kübler, Andreas Schirbel, Markus Essler, Ralph A Bundschuh, Rudolf A Werner

  • High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL.

    Molecular imaging

    Authors: Rudolf A Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Takahiro Higuchi, Philipp Hartrampf, Sebastian E Serfling, Thorsten Derlin, Constantin Lapa, Andreas K Buck, Markus Essler, Kenneth J Pienta, Mario A Eisenberger, Mark C Markowski, Laura Shinehouse, Rehab AbdAllah, Ali Salavati, Martin A Lodge, Martin G Pomper, Michael A Gorin, Ralph A Bundschuh, Steven P Rowe

  • A Novel Radiomics-Based Tumor Volume Segmentation Algorithm for Lung Tumors in FDG-PET/CT after 3D Motion Correction-A Technical Feasibility and Stability Study.

    Diagnostics (Basel, Switzerland)

    Authors: Lena Bundschuh, Vesna Prokic, Matthias Guckenberger, Stephanie Tanadini-Lang, Markus Essler, Ralph A Bundschuh

  • Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.

    Pharmaceuticals (Basel, Switzerland)

    Authors: Cristina Barca, Christoph M Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert D Windhorst, Nick Devoogdt, Kevin M Brindle, Michael Schäfers, Bastian Zinnhardt, Andreas H Jacobs